NEW YORK (GenomeWeb) – Illumina has filed a new patent infringement lawsuit against Premaitha Health in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. In the suit, Illumina alleges that Premaitha infringes on a patent it holds related to noninvasive prenatal testing.

The patent in question is one that Illumina licenses from Sequenom, the European Patent (UK) 1 524 321 B2 titled, "Non-invasive Detection of Fetal Genetic Traits." Illumina is seeking damages and injunctive relief.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

Dec
05
Sponsored by
Agilent

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.